
Professor Lisa Beck explores the chronic and persistent burden of atopic dermatitis (AD) as well as the concept of early intervention in patients with AD.

Highlights from the ADVENT educational symposium at EADV 2024 where Professors Eric Simpson, Stephan Weidinger, and Marjolein de Bruin-Weller explored the local and systemic effects of type 2 inflammation in AD and potential benefits of early intervention with regard to disease modification.
In this video from EADV 2025, Professor Metz shares exciting data from therapies recently approved or in late-stage development for CSU.

In this clip from the April WCPD 2025 symposium, Dr Amy Paller highlights CCL17 (TARC) as an important biomarker in AD.
Join leading pulmonologists Drs. Njira Lugogo, Simon Couillard, and Mario Castro, as they explore the role of type 2 inflammation in the pathogenesis of mucus plugging in the airways, the burden of excess mucus in patients with moderate-to-severe asthma, and how reducing airway mucus may lead to improved long-term patient outcomes.

In this video of the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Perla Lansang reviews the current and emerging treatment options for children with AD uncontrolled with topical therapy, including a summary of recent long-term data for advanced systemic therapies
Dr. Lawrence Eichenfield discusses the meaning of "early intervention" and its potential implications in atopic dermatitis.

Dr. Donna Culton describes the heterogenous presentation of bullous pemphigoid and how to diagnose this complicated disease.
Dr. Lawrence Eichenfield shares the cumulative burdens faced by patients with atopic dermatitis.

Join Dr. Celeste Porsbjerg as she discusses on how IL-13 contributes to mucus plugging in asthma.

In this exclusive video interview, Dr Paula Luna discusses how disease modification can be defined in AD and how IgE may be used as a biomarker in AD.

In this video from the April 2025 WCPD symposium, Dr Amy Paller discusses the pathophysiology of skin barrier dysfunction in AD and how regulating IL-4 and IL-13 signaling may lead to restoration of the skin barrier. Dr Paller goes on to explore how reducing certain biomarkers, such as CCL17 (TARC), may reduce inflammation that contributes to AD severity in pediatric patients.